Dainippon Sumitomo's Amlodin’s Switch To New Tablet Smooth
This article was originally published in PharmAsia News
At a press conference in Osaka, Dainippon Sumitomo Pharma President Kenjiro Miyatake said calcium antagonist Amlodin's switch to orally disintegrating tablets will be 60 percent complete in 2008. As the patent for Amlodin expires in July, DSP will launch generic hypertension drug irbesartan next fiscal quarter. Irbesartan has been prescribed concomitantly with Amlodin to offset competition from generic drugs. DSP will launch schizophrenia drug Lonasen in April and jointly promote it with Osaka-based Yoshitomi Yakushi. DSP has been investing in London-based Bio venture fund Apposite and will invest in more seed projects via the fund. (Click for more - Japanese language
You may also be interested in...
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.
US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.
Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.